Elevating Financial Performance: IBA's 2024 Year in Review
Louvain-la-Neuve, Belgium - IBA (Ion Beam Applications S.A.), a global leader in particle accelerator technology, has reported a remarkable turnaround for the fiscal year 2024. The company achieved record revenues and celebrated a return to profitability, primarily driven by effective backlog conversion strategies.
Record Revenue and Profitability
For the fiscal year, IBA recorded net sales of €498.2 million, representing a 7% increase compared to the previous year. The growth was notably aided by a substantial 18% rise in revenues from Other Accelerators, signaling strong demand in that sector. This stellar performance is complemented by a gross margin increase to 33.3%, up from 28.8% in 2023, fueled by enhancements in Proton Therapy margins and a higher share of revenues from Other Accelerators.
Key Financial Metrics at a Glance
Investors and stakeholders received encouraging figures, with the company’s REBIT soaring by 170% to reach €17.3 million. This impressive growth was predominantly the result of meticulously executed backlog conversion, particularly in the Other Accelerators segment, which saw a contribution of approximately €11 million to REBIT year-over-year. Furthermore, the net profit showed a remarkable shift from a loss of €9.1 million in 2023 to a net result of €9.3 million, highlighting the company's successful turnaround.
Strong Order Intake and Backlog Stability
In addition to its financial turnaround, IBA reported an impressive 11% year-over-year growth in equipment order intake, exemplified by a striking 43% increase in orders for Other Accelerators. Proton Therapy order intake also gained notable momentum, with five accelerator systems sold by the year’s end. The company's backlog remains robust, standing at an all-time high of €1.5 billion, providing exceptional clarity and confidence regarding future financial performance.
Financial Health and Future Investments
IBA's financial health is underscored by a net cash position of €33.5 million at year-end and access to €60 million undrawn credit lines. The company is poised for continued growth through strategic investments in value creation. This includes the securing of an over-subscribed Series A funding round for PanTera, which valued the company at an estimated €280 million post-money and aims to enhance global Actinium-225 production capabilities.
Organizational Changes and Future Outlook
Reflecting its evolving business model, IBA announced a new segment reporting structure organized into three focused areas: IBA Clinical, IBA Technologies, and IBA Corporate. This restructuring facilitates targeted growth strategies moving forward, effective from 2025, with pro-forma data for 2024 already available for stakeholders.
The company also witnessed leadership changes, with Henri de Romre?e stepping in as interim CFO following Soumya Chandramouli's departure. Looking ahead, the updated mid-term revenue guidance estimates a compound annual growth rate (CAGR) of 5-7% from 2024 to 2028, aiming for a REBIT margin of around 10% by 2028. IBA’s management remains optimistic about achieving at least €25 million in REBIT for 2025.
Upcoming Capital Markets Day
A dedicated Capital Markets Day is scheduled for early April, designed to provide deeper insights into each business unit's growth drivers and outline a roadmap for attaining the company's financial objectives.
Final Thoughts from Leadership
Olivier Legrain, Chief Executive Officer of IBA, expressed satisfaction with the company’s 2024 performance, stating, "We are pleased to report improved topline growth and a return to profitability in 2024. IBA successfully delivered on our aim of accelerating backlog conversion across all business units, especially the Other Accelerators division." He emphasized IBA's standing at a pivotal moment as it enters 2025 with a solid financial position, a record-high backlog, and an active project pipeline. According to Legrain, the necessary foundations for long-term profitability and sustainable growth are firmly in place.
Frequently Asked Questions
What were IBA's net sales for 2024?
IBA recorded net sales of €498.2 million for the fiscal year 2024, representing a 7% increase compared to 2023.
How did IBA's profitability change from 2023 to 2024?
In 2024, IBA transitioned from a net loss of €9.1 million in 2023 to achieving a net profit of €9.3 million.
What is IBA's backlog status?
IBA's backlog remains at an all-time high of €1.5 billion, providing substantial future revenue visibility.
What are IBA's growth expectations for the next few years?
The company anticipates a revenue compound annual growth rate (CAGR) of 5-7% from 2024 to 2028, aiming for a REBIT margin of approximately 10% by 2028.
What is IBA's new organizational structure?
IBA has restructured into three focused entities: IBA Clinical, IBA Technologies, and IBA Corporate, effective from 2025, to drive strategic growth.
